Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Melanoma

Free Subscription Articles published in Arch Pathol Lab Med Retrieve available abstracts of 7 articles: HTML format

Single Articles

May 2022
1. BRESLER SC, Simon C, Shields CL, McHugh JB, et al
   Conjunctival Melanocytic Lesions.
   Arch Pathol Lab Med. 2022;146:632-646.
   PubMed     Abstract available
   
   
   March 2022
2. TSANG M, Petkiewicz S
   Impact of Reflex Testing for BRAF Mutational Status in Advanced Melanoma.
   Arch Pathol Lab Med. 2022 Mar 28. pii: 479609. doi: 10.5858/arpa.2021-0219.
   PubMed     Abstract available
   
   
   December 2021
3. EIGER-MOSCOVICH M, Eagle RC, Milman T
   beta-Catenin and Periodic Acid-Schiff Distinguish Granular Cell Nevus From Deep Penetrating Nevus.
   Arch Pathol Lab Med. 2021;145:1475-1476.
   PubMed    
   
   
   
4. RONEN S, Al-Rohil RN, Keiser E, Jour G, et al
   Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management.
   Arch Pathol Lab Med. 2021;145:1505-1515.
   PubMed     Abstract available
   
   
   January 2021
5. WANG M, Aung PP, Prieto VG
   Standardized Method for Defining a 1-mm2 Region of Interest for Calculation of Mitotic Rate on Melanoma Whole Slide Images.
   Arch Pathol Lab Med. 2021 Jan 8. pii: 450730. doi: 10.5858/arpa.2020-0137.
   PubMed     Abstract available
   
   
   December 2020
6. MEJBEL HA, Torres-Cabala CA, Milton DR, Ivan D, et al
   Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma.
   Arch Pathol Lab Med. 2020 Dec 8. pii: 449247. doi: 10.5858/arpa.2020-0308.
   PubMed     Abstract available
   
   
   October 2020
7. CHO WC, Wang WL, Milton DR, Ingram DR, et al
   Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma.
   Arch Pathol Lab Med. 2020 Oct 14. pii: 445970. doi: 10.5858/arpa.2020-0330.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: